Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Phase 3
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F)
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- MidLantic Urology
- Target Recruit Count
- 113
- Registration Number
- NCT05799248
- Locations
- 🇺🇸
MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath